info@symbiosisip.co.uk

The EPO Enlarged Board of Appeal confirms that plants and animal products produced by essentially biological processes are not patentable.

Author: Astrid Lorenz | astrid@symbiosisip.co.uk

26 May 2020

#

In the decision G3/19 dated 14 May 2020, the EBA found that plants, plant materials or animals, if exclusively obtained by an essentially biological process are excluded from patent protection.

This is the result of a lengthy legal dispute concerning the patentability of methods and products involving essentially biological processes (e.g. cross-breeding) and follows a Technical Board of Appeal Decision T 1063/18 stating the EPC was not clear on this matter.

To put this into perspective there are currently more than 250 pending patent cases to which this decision will apply.

Specifically whilst Art 53(b) EPC states that “European patents shall not be granted in respect of essentially biological processes for the production of plants or animals“, this was interpreted to mean the exclusion of essentially biological processes did not extend to products and so did not exclude patent protection for plant material such as fruit (Decision G2/12 and G2/13).

New Rule 28(2) EPC was introduced in July 2017 to facilitate the correct interpretation of Art 53(b) EPC. It states that “European patents shall not be granted in respect of plants and animals exclusively obtained by means of an essentially biological process”; however, in the Technical Board of Appeal Decision T1063/18 this clarification was not found to be helpful.

Following the decision T 1063/18, the EPO President referred the matter to the EBA to provide clarification.  The EBA concluded that product claims directed to plants, plant material or animals, if exclusively obtained by means of an essentially biological process, are not patent eligible.

Summary

In summary, according to G 3/19, plants and animal products obtained by essentially biological processes are not patentable.

This decision has no retroactive effect on European Patents granted before 1 July 2017 or applications having an effective filing date prior that date.

If you have any queries on the Decision or how you may be affected by the changes, please do not hesitate to contact a member of our Team who would be happy to assist with your queries.

"Excellent technical licensing and deal-making skills, [a] can-do attitude and an inherent sense of value to each assignment"

Senior Leader, Corporate

"Andrew lived up to our expectations, helping us take a very hard negotiation over the line. We enjoyed working with him and would do so again. I would definitely recommend him to organisations trying to navigate IP licensing negotiations"

UK CEO

"Mark Hoggins consistently delivers excellent service and detailed and informed responses to examiners, and helps clients understand each step and grow in their understanding of the IP protection process."

IAM Patent 2022 Client Interview

"The work carried out by Symbiosis has always been of high quality. The team have a wealth of experience and understanding in life sciences, which means they are able to provide advice on patent filing from the earliest stage right through prosecution."

IAM Patent 2022 Client Interview

"Julie always asks the right questions and grasps the heart of the invention easily. Julie expresses herself very clearly and it is straightforward to communicate with her, in both written and oral form. She presents commercial strategies, thanks to her long experience in the field and concrete exposure to challenges that she has been able to overcome."

IAM Patent 2022 Client Interview

"Lee Samuel readily understands technology and consistently demonstrates thorough knowledge of patent law, great attention to detail and efficient organisational skills, leading to successful grants."

IAM Patent 2022 Client Interview

"Driven, dedicated and knowledgeable in the whole spectrum of work covering commercialisation of technology"

UK University Senior Tech Transfer

"It is a privilege to work with Symbiosis."

Prof. Richard Ross, CSO
Asterion Limited

"Their communications are clear and always in good time for action to be taken. They have established a good network of foreign associates and we have recently had successful filings in the USA, Japan and China without a need for extensive office action and its associated costs."

IAM Patent 2022 Client Interview

"Result oriented, very responsive, a value creator and a person with a clear vision and strategy"

Senior Corporate Counsel

"Symbiosis maximises the value of IP generated by our inventors in a cost effective and efficient manner that meets our commercial objectives."

Martin Whitaker
CEO, Diurnal

"Our two companies collaborate very well together to optimise the commercial benefits of the Glycologic Limited portfolio of activities."

Richard Tester
Managing Director, Glycologic Limited

"Symbiosis dives deep into the science and data and then gives an excellent assessment of the potential for the patent to be granted and the value of said patent."

IAM Patent 2022 Client Interview

"Andrew gave us the confidence that the final terms agreed were fair and in line with the current best practice"

UK University Head of Tech Transfer

"It is not an exaggeration to state that our confidence in Rob and Symbiosis is such that the strategic direction of our company has been IP-led at all times."

IAM Patent 2022 Client Interview

"One of those rare breeds who manage to combine considerable technical expertise with a keen business sense"

Senior Leader, Corporate

"Cardiff University has a longstanding relationship with Symbiosis IP and we have always experienced a consistently high quality range of IP services. We particularly appreciate the ability to provide bespoke advice for academic, TTO or industry audiences as appropriate and this has contributed significantly to our translational successes across the life sciences portfolio."

Rhodri Turner
Senior Technology Transfer Officer, Cardiff University

"Vast experience in commercialising science and technology"

Senior UK Patent Attorney

"The service provided by Symbiosis is personal, efficient and highly professional."

IAM Patent 2022 Client Interview

Our use of cookies

We use necessary cookies to make our site work. We'd also like to set analytics cookies that help us make improvements by measuring how you use the site. These will be set only if you accept.

For more detailed information about the cookies we use, see our Cookies page. Cookie Control Link Icon

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We'd like to set Google Analytics cookies to help us improve our website by collecting and reporting information on how you use it. The cookies collect information in a way that does not directly identify anyone. For more information on how these cookies work please see our 'Cookies page'.